



Get MarketWatch Anytime, Anywhere.

More

Enter Symbol(s) or Keyword(s)

Welcome, please [sign in](#).
[My Portfolio](#) • [Community](#) • [VSE](#) • [Alerts](#)

FRONT PAGE **NEWS & COMMENTARY**

[Columnists](#) [First Take](#) [Special Reports](#) [Blogs](#) [Podcasts](#) [Industry News](#) [Economy & Politics](#) [Newsletters](#) [Obama's Challenge](#)

LATEST NEWS [\[AIG\]](#) AIG to cooperate with U.K. probe into AIG Financial Products

PRESS RELEASE

U.S. Cardiologist Reports Successful Treatment of Cardiovascular Disease Using Patients' Own Adult Stem Cells Clinical Results of Adult Stem Cell Therapy Presented at International Regenerative Biomedical Technology Conference

Last update: 6:00 a.m. EST Nov. 14, 2008



DUBAI, U.A.E., Nov 14, 2008 (BUSINESS WIRE) -- In a report unprecedented in the healthcare industry, Zannos Grekos, MD presented clinical data this week to the Dubai Congress on Regenerative Biomedical

Technologies demonstrating the successful treatment of end-stage cardiac diseases using Autologous Adult Stem Cell Therapy. Dr. Grekos offered cardiac nuclear scans, PET scans, and echocardiographs performed at six months and one year post-treatment, which confirm the regeneration of damaged heart tissue, the existence of new blood vessels and a dramatic improvement in heart function in patients treated with adult stem cells extracted from their own blood.

"This is real science, real medicine and real results," Grekos stated. "We have moved beyond bench research and clinical trials to show that the power of the body's adult stem cells can be harnessed. Our success rate in reversing ischemic cardiomyopathy and congestive heart failure is extremely high and with our latest technology we're capturing the same astounding cell regeneration results in other disease classifications."

Grekos, who is chief medical officer for Florida-based stem cell center Regenocyte Therapeutic, also announced that his team of physicians and scientists successfully treated a patient with Fabry disease - a previously untreatable enzyme deficiency which leads to heart and kidney failure. The patient's ejection fraction (EF) increased from 28 to 41 in just four months out from Adult Stem Cell Therapy (normal EF is 55.)

According to Dr. Grekos, "The patient no longer needs a heart transplant, which was previously the only means for arresting this disease. His kidney dialysis time has already been reduced by 10 percent, so we are looking at treating his kidney function in the near future."

Athina Kyritsis, MD and chair of Regenocyte's medical advisory committee, states, "As a physician I find one of the most exciting things this discovery offers is the potential to address many diseases currently believed to be untreatable. We are leaping off of medicine's cutting edge; this is no longer just theory."

The Treatment Process

Adult stem cells are extracted from a patient via a standard blood draw. This small, naturally occurring stem cell population is sent to a biotechnology laboratory where it is grown into millions of cells which are engineered to migrate to the part of the body needing repair. The patient receives the new cells one week later through an advanced injection and/or infusion delivery system. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged tissue means there is no possibility of rejection or tumorigenicity (cancer causing).

About the Physician

Zannos Grekos, MD is an interventional cardiologist based in Florida. He is chief medical officer for Regenocyte Therapeutic, one of the world's first clinically treating adult stem cell centers. He is associate clinical professor of Cardiology for Nova Southeastern University and has been appointed to the Science Advisory Board of Washington, D.C.'s Repair Stem Cell Institute. In February 2007, he was invited to brief the United States Senate Health Advisory Staff on the current state of stem cell research and therapy.

LATEST VIDEOS MARKETS & BUSINESS

- What's Ahead at Mobile World ...
Thu, Feb 12, 2009 - 4:51 PM
- Retail Sales Offer Little Cheer
Thu, Feb 12, 2009 - 4:18 PM
- Israel Strikes Hamas ...
Thu, Feb 12, 2009 - 3:49 PM
- Korean Missile Row Intensifies
Thu, Feb 12, 2009 - 3:46 PM
- Stimulus Bill on Track for ...
Thu, Feb 12, 2009 - 3:31 PM
- Taliban Militants Kill 20 in ...
Thu, Feb 12, 2009 - 3:18 PM
- Keynesian Stimulus?
Thu, Feb 12, 2009 - 05:52 AM
- Credit Crisis Takes Toll on ...
Thu, Feb 12, 2009 - 12:52 AM
- Chicken Housing Crisis Hits
Thu, Feb 12, 2009 - 12:21 AM
- Skepticism Surrounds Obama ...
Thu, Feb 12, 2009 - 12:01 AM

MarketWatch [More Videos](#)

Before the Bell E-newsletter

Get a daily, pre-market look at all the stocks expected to move, plus all the early news and action in Europe and Asia.

[Privacy policy](#)

MOST POPULAR

READ | E-MAILED | EDITOR'S PICK

1. [Retail sales unexpectedly jump 1% for first rise since June](#)
2. [Wall Street wasteland](#)
3. [Retail sales surprise not enough to spur futures](#)
4. [January U.S. foreclosures up 18%, but down from Dec. levels](#)
5. [Pioneer plans 10,000 job cuts, closing TV business](#)
6. [State-owned Chinalco to invest \\$19.5 billion in miner Rio Tinto](#)
7. [The 15-Minute Tip: Four bargains in blue-chip stocks](#)
8. [Why the market gagged on Treasury's plan](#)
9. [Outlook for stocks](#)
10. [US Stocks Decline Sharply At Opening; DJIA Down 150 Points](#)

[Get the Latest MarketWatch News >>](#)

PARTNER CENTER

Switch to Scottrade, get up to \$100 back

Regenocyte Therapeutic is currently using Adult Stem Cell Therapy to treat Congestive Heart Failure, Cardiomyopathy, Peripheral Artery Disease, Coronary Artery Disease, Kidney Disease, Ischemic Heart Disease, Pulmonary Disease and Early Senile Dementia. Clinical trials will begin in 2009 for patients with macular degeneration and various neurological diagnoses. Patients can call 866-216-5710 for information or consultation.

SOURCE: Regenocyte Therapeutic

Regenocyte Therapeutic

Media contact:

Beth S. Kalvin, Director of Communications & Education

239-495-2252 x306; 239-777-2227 cell

bkalvin@regenocyte.com

or

Investors contact:

Paul Schwartz, Chief Operating Officer

239-495-2252 x311

pschwartz@regenocyte.com

Copyright Business Wire 2008



Sponsored Links

AARP Auto Insurance

If You're Over 50, You Could Save \$388 On Auto Insurance With The AARP

AARP.TheHartford.com

HGH-Testosterone Therapy

We provide the best cost for HGH and Testosterone Therapy.

www.ModernTherapy.com

Stem Cell Breakthrough

Over 1500 Patients Treated for Multiple Diseases. Taking Patients!

www.Medra.com/StemCell.html

Top stories

- 9 minutes ago [Passage of stimulus eyed before weekend recess](#)
- 10:46 AM today [Fixed mortgage rates drop further: Freddie Mac](#)
- 10:18 AM today [Coca-Cola profit down on charges, but volume rises](#)

[Site Index](#) | [Topics](#) | [Archive](#) | [Help](#) | [Feedback](#) | [Media Archive](#) | [Premium Products](#) | [Mobile](#) | [RSS](#) | [Podcasts](#) | [Company Info](#) | [Advertising Media Kit](#) | [License our Content](#)

The Wall Street Journal Digital Network:

[WSJ.com](#) | [Barron's Online](#) | [BigCharts](#) | [Virtual Stock Exchange](#) | [All Things Digital](#) | [MarketWatch Community](#)

[RealEstateJournal.com](#) | [Financial News Online](#) | [WSJ.com Small Business](#) | [FiLife - Personal Finance](#)

MarketWatch

Copyright © 2009 MarketWatch, Inc. All rights reserved.

By using this site, you agree to the [Terms of Use](#) and [Privacy Policy](#).

MarketWatch.com: [Stock Market Quotes](#) - [Business News](#) - [Financial News](#)

Intraday data provided by [Interactive Data Real Time Services](#), a division of Interactive Data Corp. and subject to [terms of use](#). Historical and current end-of-day data provided by [Interactive Data Pricing and Reference Data](#). More information on [NASDAQ traded symbols](#) and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.

E*TRADE Get 100 Free Trades.
E*TRADE Securities.

AMERITRADE No maintenance fees. **GO**

Trade free for 30 days at TD AMERITRADE.

LATEST HEADLINES
MARKETS NEWS



Gold seesaws after hitting seven-month high ...
Thu, Feb 12, 2009 - 11:47 AM

Treasurys climb after jobless data underscore ...
Thu, Feb 12, 2009 - 11:47 AM

US Stocks Remain Lower With Investors Wary Of ...
Thu, Feb 12, 2009 - 11:40 AM

Natural gas shares fall on inventory surprise ...
Thu, Feb 12, 2009 - 11:38 AM

MarketWatch

More Markets News